Tenax Therapeutics, Inc. (TENX) Stock Price

TENXStock

$2.32−69.17%52W

Market Cap$86.82M

P/E—

PEG Ratio1.44

Div yield—

Beta0.99

TENX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-96.45%

Price vs S&P 500 (4W)-91.34%

PEG Ratio1.44

VGM Score13.52

Book Value / Share (Quarterly)$3.56

P/TBV (Annual)3.79x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.44

Price vs S&P 500 (YTD)-96.78%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-10115.82%

EPS (TTM)$-1.47

10-Day Avg Trading Volume11.17M

EPS Excl Extra (TTM)$-1.47

EPS (Annual)$-1.34

ROI (Annual)-54.19%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-12872.94%

Cash / Share (Quarterly)$3.69

ROA (Last FY)-50.47%

Revenue Growth TTM (YoY)-82.93%

EBITD / Share (TTM)$-1.55

ROE (5Y Avg)-337.11%

Operating Margin (TTM)-10390.47%

Cash Flow / Share (Annual)$-3.84

P/B Ratio0.57x

P/B Ratio (Quarterly)3.40x

Net Income / Employee (Annual)$-3,757,100

EV / Revenue (TTM)-1075.97x

Net Interest Coverage (TTM)-320.28x

ROA (TTM)-57.42%

EPS Incl Extra (Annual)$-1.34

Current Ratio (Annual)14.56x

Quick Ratio (Quarterly)14.65x

3-Month Avg Trading Volume2.93M

52-Week Price Return-69.17%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$10164.00

P/S Ratio (Annual)1317.05x

Asset Turnover (Annual)0.00x

52-Week High$19.40

Operating Margin (5Y Avg)-10572.22%

EPS Excl Extra (Annual)$-1.34

Tangible BV CAGR (5Y)47.56%

26-Week Price Return-85.20%

Quick Ratio (Annual)13.78x

13-Week Price Return-85.03%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)15.07x

Enterprise Value$-53.05M

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-55.21%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)0.00x

Pretax Margin (Annual)-28563.49%

Cash / Share (Annual)$10.47

3-Month Return Std Dev198.98%

Gross Margin (5Y Avg)57.92%

Net Income / Employee (TTM)$-4,633,100

ROE (Last FY)-54.19%

Net Interest Coverage (Annual)-17.63x

EPS Basic Excl Extra (Annual)$-1.34

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.47

Receivables Turnover (Annual)0.00x

ROI (TTM)-61.55%

P/S Ratio (TTM)1317.05x

Pretax Margin (5Y Avg)-12872.94%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$17141.00

Price vs S&P 500 (52W)-87.48%

Year-to-Date Return-84.82%

5-Day Price Return8.82%

EPS Normalized (Annual)$-1.34

ROA (5Y Avg)-201.92%

Net Profit Margin (Annual)-28563.49%

Month-to-Date Return-86.50%

Cash Flow / Share (TTM)$-0.49

EBITD / Share (Annual)$-1.44

Operating Margin (Annual)-30054.16%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-292.37%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.47

P/TBV (Quarterly)1.04x

P/B Ratio (Annual)0.78x

Inventory Turnover (TTM)0.00x

Pretax Margin (TTM)-10115.82%

Book Value / Share (Annual)$10.42

Price vs S&P 500 (13W)-87.83%

Beta0.99x

Revenue / Share (TTM)$0.00

ROE (TTM)-61.55%

52-Week Low$1.31

gGradeF

mGradeD

vgmGradeF

TENX Earnings Surprise History

Q2 25-0.27est. -0.45

Q3 25-0.40est. -1.12

Q4 25-0.38est. -0.41

Q1 26-0.35est. -0.40

Q2 26-0.35est. -0.36

TENX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.33

4.25

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
TENXTenax Therapeutics, Inc.	—	F	D	$2.32
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Tenax Therapeutics, Inc.

Tenax Therapeutics is a specialty pharmaceutical company focused on cardiovascular and pulmonary diseases with high unmet medical needs. The company's lead asset is levosimendan (North American rights), currently in Phase 2 development for pulmonary hypertension associated with heart failure with preserved ejection fraction.